Antidepressants : from biogenic amine to new mechanisms of action /: from biogenic amine to new mechanisms of action. ([2019])

• Record Type: Book
• Further Information: Note: Matthew Macaluso, Sheldon H. Preskorn, editors.
• Editors: Macaluso, Matthew; Preskorn, Sheldon
• Contents: Intro; Preface; Contents; Impact, Diagnosis, Phenomenology, and Biology; 1 Section 1: Prevalence; 2 Impact; 2.1 Disability and Economic Impact; 2.2 Suicide; 3 Diagnosis; 3.1 History; 3.2 Operational Definitions; 3.3 Subtypes; 4 Measurement; 4.1 Self-Rated Scales; 4.2 Clinician-Rated Scales; 5 Phenomenology; 6 Diagnostic Boundaries; 7 Biology; References; Tricyclic Antidepressants and Monoamine Oxidase Inhibitors: Are They Too Old for a New Look?; 1 Historical Background 2 Studies Comparing MAOI and TCA Antidepressants: Do Certain Subtypes of Depression Respond Selectively to One Class of Antide...3 More Recent Studies of Tricyclic Antidepressants and Monoamine Oxidase Inhibitors; 4 The Under-Prescribing of Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: A Justifiable Phenomenon?; References; Clinical Implications of the STAR*D Trial; 1 Introduction and Overview of STAR*D; 1.1 Participants; 1.2 Treatment Outcomes; 1.3 Treatment Steps; 1.4 Treatment Delivery; 1.5 Continuation Phase Treatment; 2 Who Is Being Treated for Depression in Practice? 2.1 How Comparable Are Depressed Patients in Primary and Psychiatric Care Settings?2.2 Are FDA Registration Trial Participants Representative of Depressed Patients Treated in Practice?; 2.3 Clinical Implications; 3 Treatment Outcomes with the Initial Medication Treatment Step with a Selective Serotonin Reuptake Inhibitor (SSRI); 3.1 When and How Often Does Response and Remission Occur with an SSRI; 3.2 Can Baseline Features Tell Us Who Will Respond or Remit with the Initial SSRI?; 3.3 What Are the Long-Term Outcomes Following a Successful First-Step SSRI? 3.4 Does the Prior Course of MDD Predict Acute or Longer-Term Treatment Outcomes with Citalopram?3.5 Clinical Implications; 4 Treatment Outcomes with the Second Medication Treatment Step; 4.1 Which Second-Step Treatment Options Are Preferred by Which Patients?; 4.2 When the Initial SSRI Fails and a Medication Switch Is Provided, Do Pharmacological Differences Matter?; 4.3 Which Augmentation Strategy Is More Effective, Bupropion-SR or Buspirone?; 4.4 How Did Augmentation with Cognitive Behavior Therapy Compare with Medication Augmentation? 4.5 How Did Switch to Cognitive Therapy Compare with Switch to Medication?4.6 Follow-Up After the Second Treatment Step; 4.7 Clinical Implications; 5 Selecting Among Switch Treatments at the Second Medication Treatment Step; 5.1 What Are the Overall and Differential Predictors of Remission (Baseline Sociodemographic, Clinical, and First-Step Treatme...; 5.2 What Are the Overall and Differential Predictors (Baseline Sociodemographic, Clinical, and First-Step Treatment Features) ...; 5.3 Clinical Implications; 6 Treatment Outcomes with the Third Medication Treatment Step
• Publisher Details: Cham, Switzerland : Springer
• Publication Date: 2019
• Extent: 1 online resource
• Subjects: 615.7/8; Antidepressants; Electronic books; Electronic books
• Languages: English
• ISBNs: 9783030109493; 3030109496
• Related ISBNs: 9783030109486; 3030109488
• Notes: Note: Description based on online resource; title from digital title page (viewed on July 12, 2019).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.